(via TheNewswire)

Also Announces Extension of IR Program

Vancouver, Canada – May 5, 2026 - TheNewswire – Redwood AI Corp. (CSE: AIRX ) (OTCQB: RDWCF ) (Frankfurt: Y0N , WKN: A422EZ ) (" Redwood " or the " Company ") is pleased to announce the appointment of Dr. Matthew A. Roberts as Public Safety and Defense Advisor to the Company. Redwood is continuing to advance the strategic positioning of its proprietary AI-powered chemical synthesis platform, Reactosphere (“ Platform ”), across a broader range of potential applications, including public safety, biosecurity, health security, and certain defense-related areas. As the Company expands its focus in these sectors, Redwood is working to strengthen its advisory bench with leaders whose experience spans science, innovation, and the development of technologies intended to address complex societal and operational challenges. In this context, Redwood is pleased to welcome Dr. Roberts as Public Safety & Defense Advisor.

Over the course of his 25-year career, Dr. Roberts has held senior executive roles at leading companies including Nestlé, Abbott, Pharmavite, and Niagen Bioscience. His experience includes establishing a corporate venture fund at Nestlé focused on health innovation, co-leading at Abbott a public-private partnership with the University of Illinois that helped create the Center for Nutrition, Learning, and Memory, and expanding external research efforts at Niagen Bioscience, formerly ChromaDex, in support of peer-reviewed publications, regulatory progress, and new business areas focused on mitochondrial health. He also advises emerging companies and nonprofit organizations and has contributed to peer-reviewed work relating to scientific and technological innovation in human health. Dr. Roberts holds a Ph.D. in Toxicology from Cornell University, an MBA from Washington University in St. Louis, and a B.Sc. in Molecular Biology from Purdue University.

In his role as Public Health, Public Safety, and Defense Advisor, Dr. Roberts will provide strategic business and technical guidance to Redwood on the application of its artificial intelligence platform to complex challenges at the intersection of public health and public safety. His work focuses on translating advanced chemistry and AI capabilities into operational systems that support frontline professionals across law enforcement, healthcare, and regulatory decision-making. Dr. Roberts currently serves as Managing Director of Aidos Innovations, a nonprofit translational science institute developed in collaboration with the University of British Columbia and the IMAPP research program at Vancouver General Hospital. Aidos is focused on advancing technologies that bridge clinical insight, scientific innovation, and system-level implementation in response to the evolving opioid crisis and related public health challenges. Through this lens, Dr. Roberts brings experience in developing and operationalizing platforms such as Track & Trace, an integrated chemical intelligence system combining advanced analytical chemistry, data infrastructure, and cross-sector collaboration to generate actionable insights on illicit drug supply and its impact on communities.

The Company also a announces that it has extended the term of its engagement with MCS Market Communication Service GmbH (business address: Saarlandstraße 28 58511 Lüdenscheid, Germany, email: info@mcsmarket.de; telephone: +491772481220; and website: www.mcsmarket.de) ("MCS") to provide market awareness and corporate communications services, including through content creation, project management, third-party media distribution, and digital market awareness initiatives (the “Services”). The Company will pay a cash fee of CAD $900,000 for the Services (the “Consideration”). The Services are scheduled to run until July 30, 2026, or budget exhaustion, and is structured to allow for ongoing evaluation and, accordingly, may be shortened or extended at the discretion of the Company. No securities have been provided to MCS or its principals as compensation. The Company believes that maintaining consistent, compliant market awareness is an important component of supporting visibility, and long-term shareholder base development.

About Redwood AI Corp.

Redwood AI uses advanced artificial intelligence to accelerate chemistry R&D, with the aim of assisting in drug discovery and development, and furthering defense and safety solutions. The Company combines expertise in chemistry, AI, and manufacturing to streamline drug synthesis and scale-up. Redwood AI’s platform is designed to enable faster, more efficient development of new therapies and chemistry-driven applications.

ON BEHALF OF REDWOOD AI CORP.,

“ Louis Dron ”

Chief Executive Officer

For more information, please contact:

Louis Dron

Chief Executive Officer

Tel: +1 888 530 8488

investors@redwoodai.com

The CSE and Information Service Provider have not reviewed and do not accept responsibility for the accuracy or adequacy of this release.

Forward-Looking Statements Caution .  This news release contains statements and information that, to the extent they are not historical fact, may constitute “forward-looking information” within the meaning of applicable securities legislation. Forward-looking information is generally identified by words such as “believe”, “expect”, “anticipate”, “estimate”, “intend”, “plan”, “may”, “should”, “will”, “potential” and similar expressions and, in this news release, includes statements relating to the development and potential deployment of the AI-powered Platform, the expectation that the Platform may be utilized for drug discovery or development or to further defense or safety solutions, and the expectation that the Company’s advisory board members will be successful in enhancing the use cases for the Platform. Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on it, as actual results may differ materially from those expressed or implied. Forward-looking information inherently involves risks and uncertainties, many of which are beyond the Company’s control. The forward-looking information contained in this news release is made as of the date hereof, and the Company undertakes no obligation to publicly update or revise such information, whether as a result of new information, future events or otherwise, except as required by applicable laws.

Copyright (c) 2026 TheNewswire - All rights reserved.